Results 11 to 20 of about 37,267 (288)
Be SMART About AL Amyloidosis [PDF]
Mayo Clinic Proceedings, 2021 n ...
Palladini, Giovanni, Merlini, Giampaolo
openaire +5 more sources
Orphanet Journal of Rare Diseases, 2022 Background Systemic amyloidosis is caused by the deposition of misfolded protein aggregates in tissues, leading to progressive organ dysfunction and death.
Roberta Shcolnik Szor +15 more
doaj +1 more source
Blood, 2022 Abstract Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove ...
Ashutosh D. Wechalekar +1 more
openaire +3 more sources
PLoS ONE, 2022 BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy +11 more
doaj +1 more source
Systemic Immunoglobulin Light Chain Amyloidosis Presenting as Painful Penile Ulcers
Annals of Internal Medicine: Clinical Cases, 2022 Immunoglobulin light chain (AL) amyloidosis is a systemic form of amyloidosis that commonly affects the heart, kidney, liver, and nervous system. Penile involvement in AL amyloidosis is rare and thus often not considered in the differential diagnosis for
Crystal Lihong Yan +3 more
doaj +1 more source
Management of AL amyloidosis in 2020 [PDF]
Hematology, 2020 Abstract In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. Organ involvement determines the clinical manifestations, but symptoms are usually recognized late.
Palladini, G., Milani, P., Merlini, G.
openaire +7 more sources
Aggregation in AL Amyloidosis [PDF]
Biophysical Journal, 2014 Systemic light chain amyloidosis (AL amyloidosis) is a rare but fatal systemic amyloid disease. It usually strikes in the wake of myeloma, a form of cancer that affects plasma cells in the adaptive immune system. During plasma cell development from primary B cells, the immunoglobulin light chain (LC) genes undergo several rearrangements that leave each
Kathrin Andrich, Jan Bieschke
openaire +2 more sources
Supportive Care in AL Amyloidosis [PDF]
Acta Haematologica, 2020 Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response.
Joan Bladé +5 more
openaire +3 more sources
Difficulties in diagnosis of primary AL-amyloidosis
Онкогематология, 2021 Objective of the study: analysis of AL-amyloidosis (AL-A) diagnostics in real clinical practice and to determine the main approaches for the earlier detection of this disease.Materials and methods.
V. A. Khyshova +3 more
doaj +1 more source
Severe Obstructive Cholestasis and Hypercalcemia Caused by Light-Chain Amyloidosis: A Case Report [PDF]
Iranian Journal of Medical Sciences, 2022 Gastrointestinal amyloidosis is a condition caused by the deposition of extracellular protein fragments. It can be associated with complex and diverse pathways and can have numerous manifestations and etiologies.
Zahra Davoudi +3 more
doaj +1 more source